Submitted:
05 May 2023
Posted:
06 May 2023
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Study Design, Inclusion Criteria and Ethics Approval
2.2. Material
2.2.1. Clinical data
2.3. Sample Collection
2.4. Laboratory Procedures
2.5. Statistical Analysis
3. Results
3.1. Demographics
3.2. SARS-CoV-2
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- COVID live - Coronavirus statistics - worldometer. Available online: https://www.worldometers.info/coronavirus/. (accessed on 15 Sep 2022).
- Liaw, J.; Saadi, R.; Patel, V.A.; Isildak, H. Middle Ear Viral Load Considerations in the COVID-19 Era: A Systematic Review. Otol Neurotol 2020, 42, 217–226. [Google Scholar] [CrossRef] [PubMed]
- Deitmer, T.; Dietz, A.; Chaberny, I.F.; Pietsch, C. [The nasal and pharyngeal swab techniques during the COVID-19-pandemic - the ENT-perspective - SARS-CoV-2, Coronavirus, nasal swab, pharyngeal swab, complications]. Laryngorhinootologie 2021, 100, 517–525. [Google Scholar] [CrossRef] [PubMed]
- Cetinkaya, E.A. COVID-19 Pandemic and Otologic Surgery. J Craniofac Surg 2020, 31, e651–e652. [Google Scholar] [CrossRef] [PubMed]
- Frazier, K.M.; Hooper, J.E.; Mostafa, H.H.; Stewart, C.M. SARS-CoV-2 Virus Isolated From the Mastoid and Middle Ear: Implications for COVID-19 Precautions During Ear Surgery. JAMA Otolaryngol Head Neck Surg. 2020, 146, 964–966. [Google Scholar] [CrossRef] [PubMed]
- Kurabi, A.; Pak, K.; DeConde, A.S.; Ryan, A.F.; Yan, C.H. Immunohistochemical and qPCR Detection of SARS-CoV-2 in the Human Middle Ear Versus the Nasal Cavity: Case Series. Head Neck Pathol 2022, 16, 607–611. [Google Scholar] [CrossRef] [PubMed]
- Jeican, I.I.; Aluaș, M.; Lazăr, M.; Barbu-Tudoran, L.; Gheban, D.; Inișca, P.; Albu, C.; Tripon, S.; Albu, S.; Siserman, C.; Vica, M.L.; Muntean, M.; Opincariu, I.; Junie, L.M. Evidence of SARS-CoV-2 Virus in the Middle Ear of Deceased COVID-19 Patients. Diagnostics (Basel) 2021, 11, 1535. [Google Scholar] [CrossRef] [PubMed]
- Kesser, B.W. News Flash!—SARS-CoV-2 Isolated From the Middle Ear and Mastoid. JAMA Otolaryngol Head Neck Surg 2020, 146, 966–967. [Google Scholar] [CrossRef] [PubMed]
- Austrian Agency for Health and Food Safety, (AGES Österreichische Agentur für Gesundheit und Ernährungssicherheit). Available online: https://www.ages.at/en/ (accessed on 01 Sep 2022).
- Ripley, B.D. The R project in statistical computing. MSOR connect 2001, 1, 23–25. [Google Scholar] [CrossRef]
- Sigrist, C.J.; Bridge, A.; Le Mercier, P. A potential role for integrins in host cell entry by SARS-CoV-2. Antiviral Res 2020, 177, 104759. [Google Scholar] [CrossRef] [PubMed]
- Wanna, G.B.; Schwam, Z.G.; Kaul, V.F.; Cosetti, M.K.; Perez, E.; Filip, P.; Javaid, W.; Kandel, A.; Paniz-Mondolfi, A.; Govindaraj, S.; Genden, E.M. COVID-19 sampling from the middle ear and mastoid: A case report. Am J Otolaryngol 2020, 41, 102577. [Google Scholar] [CrossRef] [PubMed]
- Ayache, S.; Kutz, W.; Isaacson, B.; Badr-El-Dine, M.; Nogueira, J.F.; Marchioni, D.; Presutti, L. COVID-19 and ear endoscopy in otologic practices. Eur Arch Otorhinolaryngol 2021, 278, 2133–2135. [Google Scholar] [CrossRef] [PubMed]
- Bhardwaj, R.; Sharma, A.; Singhal, B. Covid-19 and Ear Surgery: Treatment Strategies and Triage during the Post-lockdown Period. Indian J Otolaryngol Head Neck Surg 2021, 73, 480–485. [Google Scholar] [CrossRef] [PubMed]
- Couloigner, V.; Schmerber, S.; Nicollas, R.; Coste, A.; Barry, B.; Makeieff, M.; Boudard, P.; Bequignon, E.; Morel, N.; Lescanne, E. COVID-19 and ENT Surgery. Eur Ann Otorhinolaryngol Head Neck Dis 2020, 137, 161–166. [Google Scholar] [CrossRef] [PubMed]
- El-Anwar, M.W.; Elzayat, S.; Fouad, Y.A. ENT manifestation in COVID-19 patients. Auris Nasus Larynx 2020, 47, 559–564. [Google Scholar] [CrossRef] [PubMed]
- Almufarrij, I.; Uus, K.; Munro, K.J. Does coronavirus affect the audio-vestibular system? A rapid systematic review. Int J Audiol 2020, 59, 487–491. [Google Scholar] [CrossRef] [PubMed]
- Munro, K.J.; Uus, K.; Almufarrij, I.; Manchaiah, V. Persistent self-reported changes in hearing and tinnitus in post-hospitalisation COVID-19 cases. Int J Audiol 2020, 59, 889–890. [Google Scholar] [CrossRef] [PubMed]
- Mustafa, M.W.M. Audiological profile of asymptomatic Covid-19 PCR-positive cases. Am J Otolaryngol 2020, 41, 102483. [Google Scholar] [CrossRef] [PubMed]
- Maharaj, S.; Bello Alvarez, M.; Mungul, S.; Hari, K. Otologic dysfunction in patients with COVID-19: A systematic review. Laryngoscope Investig Otolaryngol 2020, 5, 1192–1196. [Google Scholar] [CrossRef] [PubMed]
- Almufarrij, I.; Munro, K.J. One year on: an updated systematic review of SARS-CoV-2, COVID-19 and audio-vestibular symptoms. Int J Audiol 2020, 60, 935–945. [Google Scholar] [CrossRef] [PubMed]
- Zou, L.; Ruan, F.; Huang, M.; Liang, L.; Huang, H.; Hong, Z.; Yu, J.; Kang, M.; Song, Y.; Xia, J.; Guo, Q.; Song, T.; He, J.; Yen, H.-L.; Peiris, M.; Wu, J. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N Engl J Med 2020, 382, 1177–1179. [Google Scholar] [CrossRef] [PubMed]



| Parameters | Total | Children | Adults |
|---|---|---|---|
| Number of Patients (%) | 102 (100) | 63 (61.76) | 39 (38.24) |
| Women (%) | 45 (44.12) | 32 (50.79) | 13 (33.33) |
| Men (%) | 57 (55.88) | 31 (49.21) | 26 (66.67) |
| Age Median; (IQR) [y] | 5.50 (43) | 4 (2) | 51 (18.50) |
| Weight Median (IQR) [kg] | 25.50 (56.12) | 18 (6) | 80 (22) |
| Type of Surgery | |||
| Acute Surgery (%) | 3 (2.94) | 0 (0) | 3 (7.69) |
| Elective Surgery (%) | 99 (97.06) | 63 (100) | 36 (92.31) |
| Tympanic Membrane Incision, Tympanostomy Tube Insertion or Removal (%) | 75 (73.53) | 60 (95.24) | 15 (38.46) |
| Tympanoplasty ± Mastoidectomy (%) | 18 (17.65) | 3 (4.76) | 15 (38.46) |
| Stapesplasty (%) | 3 (2.94) | 0 (0) | 3 (7.69) |
| Implantation (CI, VSB; %) | 6 (5.88) | 0 (0) | 6 (15.38) |
| Indication for Operation | |||
| Otosclerosis (%) | 3 (2.94) | 0 (0) | 3 (7.69) |
| Hearing Loss (%) | 7 (6.86) | 0 (0) | 7 (17.95) |
| OME, AOM, Eustachian Tube Dysfunction (%) | 67 (65.69) | 53 (84.13) | 14 (35.90) |
| CSOM (%) | 17 (16.67) | 8 (12.70) | 9 (23.08) |
| CHOL (%) | 8 (7.84) | 2 (3.17) | 6 (15.38) |
| Parameters | Total (%) | Children (%) | Adults (%) | p-Value |
|---|---|---|---|---|
| ASA-Score I II III IV-VI |
||||
| 70 (68.63) | 57 (90.48) | 13 (33.33) | ||
| 29 (28.43) | 6 (9.52) | 23 (58.97) | <0.001 | |
| 3 (2.94) | 0 | 3 (7.69) | ||
| 0 | 0 | 0 | ||
| Cardiovascular Diseases | 15 (14.71) | 2 (3.17) | 13 (33.33) | <0.001 |
| Reflux | 11(10.78) | 1 (1.59) | 10 (25.64) | <0.001 |
| Respiratory Diseases | 8 (7.84) | 1 (1.59) | 7 (17.95) | <0.005 |
| Obstructive Sleep Apnea | 4 (3.92) | 3 (4.76) | 1 (2.56) | NA |
| Craniofacial Anomalies | 4 (3.92) | 2 (3.17) a | 2 (5.13) b | NA |
| Thyroid Gland Disease | 4 (3.92) | 0 (0) | 4 (10.26) | NA |
| Diabetes Mellitus | 3 (2.94) | 0 (0) | 3 (7.69) | NA |
| Wegener Disease | 1 (0.98) | 0 (0) | 1(2.56) | NA |
| Down Syndrome | 1 (0.98) | 0 (0) | 1(2.56) | NA |
| Muscle Hypotonia | 1 (0.98) | 1(1.59) | 0 (0) | NA |
| Allergy | 9 (8.82) | 6 (9.52) | 3 (7.69) | 1 |
| Parameters | Total (%) | Children (%) | Adults (%) |
|---|---|---|---|
| Vaccinated Patients | 25 (24.51) | 2 (3.17) | 23 (58.97) |
| 1. Comirnaty (BioNTech/Pfizer) 2. Jannsen (Johnson & Johnson) 3. Spikevax (Moderna) 1. + 2. Comirnaty + Jannsen Vaccination of unknown kind No vaccination |
19 (18.63) | 19 (18.63) | 19 (18.63) |
| 1 (0.98) | 1 (0.98) | 1 (0.98) | |
| 1 (0.98) | 1 (0.98) | 1 (0.98) | |
| 1 (0.98) | 1 (0.98) | 1 (0.98) | |
| 3 (2.94) | 3 (2.94) | 3 (2.94) | |
| 77 (75.49) | 77 (75.49) | 77 (75.49) | |
| Time between last Vaccination and Operation Min (d) Max (d) Median (d) IQR (d) Mittelwert (d) NA |
|||
| 6 | 95 | 6 | |
| 154 | 130 | 154 | |
| 48 | 44 | ||
| 61 | 59 | ||
| 62 | 113 | 57 | |
| 1 | 0 | 1 | |
| Patients with Covid-19 Infection in History | 13 (12.75) | 9 (14.29) | 4 (10.26) |
| Time between the last Covid-19 Infection and Operation Min (d) Max (d) Median (d) IQR (d) Mittelwert (d) NA |
|||
| 7 | 7 | 8 | |
| 495 | 495 | 408 | |
| 132 | 103 | 272 | |
| 318 | 140 | 295 | |
| 189 | 166 | 240 | |
| 0 | 0 | 0 | |
| Patients with Proven Contact | 34 (33.33) | 27 (42.86) | 7 (17.95) |
| Time between the last Proven Contact and Operation Min (d) Max (d) Median (d) IQR (d) Mittelwert (d) NA |
|||
| 9 | 45 | 9 | |
| 667 | 667 | 353 | |
| 129 | 131 | 127 | |
| 127 | 129 | 97 | |
| 173 | 185 | 130 | |
| 0 | 0 | 0 | |
| SARS CoV-2 in the Ear | 2 (1.96) | 2 (3.17) | 0 (0) |
| SARS CoV-2 in the Nasopharynx | 4 (3.92) | 4 (6.35) | 0 (0) |
| SARS CoV-2 in the Filter | 0 (0) | 0 (0) | 0 (0) |
| Parameters | Patient No. 72 | Patient No. 95 | Patient No. 99 | Patient No. 101 |
|---|---|---|---|---|
| Sex and Age [y] | M 4 | M 5 | F 8 | F 4 |
| Weight [kg] | 18 | 20 | 30 | 17 |
| Type of Surgery | Elective | Elective | Elective | Elective |
| Type of Procedere | PC | PC | G | G |
| Indication for Operation | OME | OME | OME | OME |
| SARS CoV-2 in Ear (ct) | +(29.77) | +(30.03) | No | No |
| SARS CoV-2 in Nasopharynx (ct) | +(25.94) | +(32.15) | +(32.11) | +(37.06) |
| SARS CoV-2 in Filter Sample | No | No | No | No |
| Vaccination Against SARS CoV-2 | No | No | No | No |
| Covid -19 Infection Preoperatively [Days Before Operation] |
7 | No | 51 | 50 |
| Proven Contact with SARS CoV-2 Positive Person [Days Before Operation] |
No | 15 | 68 | No |
| Covid-19 Infection After Surgery | No | No | No | No |
| Additional Diseases: | No | No | No | No |
| ASA-Score | I | I | I | I |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).